In preparation for the development of a new line of products, a regulatory affairs professional is asked to
prepare a short presentation for senior management. Which of the following topics is MOST important to
cover?

During face-to-face meetings with the regulatory authority to address submission issues, what is the
BEST choice for the number of company representatives who should attend?

Which analysis method is MOST appropriate to prioritize risk and monitor the effectiveness of risk control
activities for a medical device?

During several monitoring visits, a clinical trial monitor identifies serious and repeated noncompliance on
the part of the PI. What action should the sponsor take?

According to ICH, which of the following components of study information is NOT required in a clinical
study report?